Publication Name	World Journal of Gastroenterology
Manuscript ID	79986
Country	China

Received	2022-09-13 12:51
Peer-Review Started	2022-09-13 12:53
To Make the First Decision
Return for Revision	2022-11-05 07:25
Revised	2022-11-11 07:55
Second Decision	2022-12-01 03:25
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-12-01 22:08
Articles in Press	2022-12-01 22:08
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-12-20 23:59
Publish the Manuscript Online	2022-12-27 10:06

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease
Manuscript Source	Invited Manuscript
All Author List	Yi-Han Xu, Wei-Ming Zhu and Zhen Guo
ORCID	Author(s) ORCID Number Yi-Han Xu http://orcid.org/0000-0002-9138-4614 Wei-Ming Zhu http://orcid.org/0000-0002-8900-1186 Zhen Guo http://orcid.org/0000-0002-1541-421X
Funding Agency and Grant Number	Funding Agency Grant Number Jiangsu Provincial Health Commission M2021013 Science Foundation of Jinling Hospital YYMS2021035
Corresponding Author	Zhen Guo, MD, PhD, Professor, Department of General Surgery, Affiliated Jinling Hospital, Medical School of Nanjing University, No. 305 East Zhongshan Road, Nanjing 210002, Jiangsu Province, China. guozhi0809@sina.com
Key Words	Inflammatory bowel diseases; Biologic; Dual targeted therapy; Therapeutic drug monitoring; Bispecific antibodies
Core Tip	The emergence of biologics and small molecules has significantly changed the therapies used for inflammatory bowel disease (IBD). However, the efficacy of these drugs is not satisfactory for every patient, which indicates an unmet need for optimizing the use of biologics/small molecules and for predicting therapeutic responses. Here, we describe the current status of novel biologics and small molecules and new treatment strategies to combat IBD by using more than one biologic.
Publish Date	2022-12-27 10:06
Citation	Xu YH, Zhu WM, Guo Z. Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease. World J Gastroenterol 2022; 28(48): 6888-6899
URL	https://www.wjgnet.com/1007-9327/full/v28/i48/6888.htm
DOI	https://dx.doi.org/10.3748/wjg.v28.i48.6888

Full Article (PDF)	WJG-28-6888.pdf
Full Article (Word)	WJG-28-6888.docx
Manuscript File	79986_Auto_Edited-LM.docx
Answering Reviewers	79986-Answering reviewers.pdf
Audio Core Tip	79986-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	79986-Conflict-of-interest statement.pdf
Copyright License Agreement	79986-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	79986-Grant application form(s).pdf
Non-Native Speakers of English Editing Certificate	79986-Language certificate.pdf
Peer-review Report	79986-Peer-review(s).pdf
Scientific Misconduct Check	79986-Bing-Wang JJ-2.png
Scientific Editor Work List	79986-Scientific editor work list.pdf
CrossCheck Report	79986-CrossCheck report.pdf